Drug Discovery World

MAY 15, 2024

Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173

Drugs Therapies Treatment Virus 173

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Vial

MARCH 1, 2024

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. It ensures regulatory compliance for over 15 long-term post-authorization safety studies across eight disease indications. with full-year revenue of US$23.04 of total revenue).

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52